NDA 050760 · US Antibiotics
Amoxil
Amoxicillin · Oral
Last checked: Nov 19, 2026Latest source record: May 1, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1999
Apr 15, 1999
Approved uses
1
Original approval plus efficacy supplements
Registered trials
918
176 Phase 3, 89 recruiting
FAERS reports
76,913
61,758 serious, 5,058 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 15, 2026.
1. INDICATIONS AND USAGE Adults and Pediatric Patients Upper Respiratory Tract Infections of the Ear, Nose, and Throat: Amoxicillin is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcus species. (α-and β-hemolytic isolates only), Streptococcus pneumoniae , Staphylococcus spp., or Haemophilus influenzae . Infections of the Genitourinary Tract : Amoxicillin is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Escherichia coli, Proteus mirabilis , or Enterococcus faecalis . Infections of the Skin and Skin Structure: Amoxicillin is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcus spp. (α-and β-hemolytic isolates only), Staphylococcus spp., or E. coli . Infections of the Lower Respiratory Tract: Amoxicillin is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcus spp. (α-and β-hemolytic isolates only), S. pneumoniae, Staphylococcus spp., or H. influenzae . Adults Patients only Helicobacter pylori Infection and Duodenal Ulcer Disease : Triple therapy for Helicobacter pylori (H. pylori) with clarithromycin and lansoprazole : Amoxicillin, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradicate H. pylori . Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Dual therapy for H. pylori with lansoprazole : Amoxicillin, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- AMOXIL · AMOXICILLIN 200MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · FOR SUSPENSION, ORAL · Discontinued
- AMOXIL · AMOXICILLIN 400MG/5ML · FOR SUSPENSION, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Amoxicillin" as an intervention, any sponsor and status, largest first.
- PLatform for Adaptive Trials In Perinatal UnitS - [Core Protocol]Pivotal-lookingNot yet recruiting
University of MelbourneAcademic, hospital or other
NCT06461429 · 100,000 participants (planned) · Start Nov 1, 2025 · Primary completion Dec 31, 2050
Drug: Erythromycin; Amoxicillin and Erythromycin and 4 more · For: Preterm Birth
- Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer MortalityPivotal-lookingRecruiting
International Agency for Research on CancerAcademic, hospital or other
NCT02047994 · 30,000 participants (planned) · Start Mar 2013 · Primary completion Dec 2033
Drug: Triple therapy · For: Helicobacter Pylori Infections; Atrophic Gastritis; Gastric Cancer
Sites: Riga, Latvia
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- Assessment of Use of Rapid Diagnostic Testing in the Context of Home Management With ACTsPivotal-lookingCompleted
Mbarara University of Science and TechnologyAcademic, hospital or other
NCT00720811 · 6,456 participants · Start Oct 2009 · Primary completion Jan 2012
Drug: Artemether-lumefantrine combination; amoxycillin and 2 more · For: Malaria; Pneumonia
Sites: Saponé, Burkina Faso; Kassane, Ghana; Iganga, Uganda · 4 sites in all
- Community-based Helicobacter Pylori EradicationStatus unknown
National Taiwan University HospitalAcademic, hospital or other
NCT00155389 · 5,000 participants (planned) · Start Jan 2004 · Primary completion Dec 2015
Drug: Helicobacter pylori eradication · For: Helicobacter Pylori Infection
Sites: Taipei, Taiwan · 2 sites in all
- Helicobacter Pylori Eradication and Follow-upStatus unknown
Shanghai Zhongshan HospitalAcademic, hospital or other
NCT05061732 · 4,447 participants (planned) · Start Sep 30, 2021 · Primary completion Jun 30, 2026
Drug: Rabeprazole; Bismuth potassium citrate and 7 more · For: Helicobacter Pylori Infection
Sites: Shanghai, China
- A Study to Compare Different Antibiotics and Different Modes of Fluid Treatment for Children With Severe PneumoniaPivotal-lookingCompleted
University of OxfordAcademic, hospital or other
NCT04041791 · 4,392 participants · Start Aug 19, 2019 · Primary completion Apr 5, 2024
Drug: Benzyl penicillin; Gentamicin Sulfate and 3 more · For: Pneumonia
Sites: Machakos, Kenya
- Community Case Management of the Severe Pneumonia With Oral Amoxicillin in Children 2-59 Months of AgePivotal-lookingCompleted
Aga Khan UniversityAcademic, hospital or other
NCT01192789 · 4,070 participants · Start Feb 2008 · Primary completion Mar 2010
Drug: Amoxicillin · For: Severe Pneumonia
Sites: Matiari, Pakistan
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- chronic kidney disease4,670
- acute kidney injury4,308
- diarrhoea4,294
- nausea3,864
- drug hypersensitivity3,834
- dyspnoea3,761
- rash3,718
- pain3,669
- fatigue3,428
- drug ineffective3,140
- off label use3,121
- renal failure3,073
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 538 |
| 2005 | 774 |
| 2006 | 805 |
| 2007 | 755 |
| 2008 | 891 |
| 2009 | 1,156 |
| 2010 | 1,408 |
| 2011 | 1,846 |
| 2012 | 2,222 |
| 2013 | 2,004 |
| 2014 | 2,363 |
| 2015 | 3,382 |
| 2016 | 4,361 |
| 2017 | 4,059 |
| 2018 | 7,036 |
| 2019 | 8,214 |
| 2020 | 6,415 |
| 2021 | 5,264 |
| 2022 | 5,036 |
| 2023 | 5,239 |
| 2024 | 5,229 |
| 2025 | 4,610 |
| 2026 | 3,303 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Sulopenem versus Amoxicillin/Clavulanate for the Treatment of Uncomplicated Urinary Tract Infection.
Puttagunta S, Aronin SI, Gupta J, et al. · NEJM Evid 2025 · Clinical Trial, Phase III, Comparative Study
- Identifying the Best Initial Oral Antibiotics for Adults with Community-Acquired Pneumonia: A Network Meta-Analysis.
Kurotschka PK, Bentivegna M, Hulme C, et al. · J Gen Intern Med 2024 · Systematic Review, Network Meta-Analysis
- Primary antibiotic resistance of Helicobacter pylori in the Asia-Pacific region between 1990 and 2022: an updated systematic review and meta-analysis.
Hong TC, El-Omar EM, Kuo YT, et al. · Lancet Gastroenterol Hepatol 2024 · Meta-Analysis, Systematic Review
- Low-dose or high-dose amoxicillin in vonoprazan-based dual therapy for Helicobacter pylori eradication? A systematic review and meta-analysis.
Ju KP, Kong QZ, Li YY, et al. · Helicobacter 2024 · Systematic Review, Meta-Analysis
- Ten-Day Vonoprazan-Amoxicillin Dual Therapy as a First-Line Treatment of Helicobacter pylori Infection Compared With Bismuth-Containing Quadruple Therapy.
Qian HS, Li WJ, Dang YN, et al. · Am J Gastroenterol 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: A systematic review and meta-analysis.
Zhou BG, Jiang X, Ding YB, et al. · Helicobacter 2024 · Comparative Study, Meta-Analysis
Sponsor: US Antibiotics
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.